Europe Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

Europe Kidney Cancer Diagnostics Market is projected to register a CAGR of 6.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Europe Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I, Stage II, Stage III and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and the rest of Europe), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:

Rising healthcare expenditure for better health services

Growing demand for better quality healthcare

Increase in diagnostic procedure for kidney cancer

Market Players

Some of the key market players for Europe kidney cancer diagnostics market are listed below:

BioVendor R&D

BluePrint Oy.

Canon Medical Systems Corporation

CENTOGENE N.V.

Creative Diagnostics

FUJIFILM Corporation

GeneDx, LLC

Grail

Illumina, Inc.

Invitae Corporation

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

Myriad Genetics, Inc.

Qiagen

Seimens Healthcare GmbH

Thermo Fisher Scientific Inc.

1 INTRODUCTION 84

1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87

2 MARKET SEGMENTATION 91

2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 MARKET APPLICATION COVERAGE GRID 99
2.8 TEST TYPE LIFELINE CURVE 100
2.9 DBMR MARKET POSITION GRID 101
2.10 VENDOR SHARE ANALYSIS 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103

3 EXECUTIVE SUMMARY 104

4 PREMIUM INSIGHTS 107

4.1 PESTEL ANALYSIS 108
4.2 PORTER'S 5 FORCES 109
4.3 EPIDEMIOLOGY 110
- 4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
- 4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111

5 INDUSTRY INSIGHTS 112

6 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114

7 MARKET OVERVIEW 117

7.1 DRIVERS 119
- 7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
- 7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121
- 7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
- 7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
7.2 RESTRAINTS 123
- 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
- 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
7.3 OPPORTUNITIES 124
- 7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
- 7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
- 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
- 7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
7.4 CHALLENGES 126
- 7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
- 7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127

8 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128

8.1 OVERVIEW 129
8.2 IMAGING 133
- 8.2.1 COMPUTED TOMOGRAPHY 134
- 8.2.2 ULTRASOUND 134
- 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
- 8.2.4 ANGIOGRAPHY 134
- 8.2.5 X-RAY 134
- 8.2.6 OTHERS 134
8.3 BLOOD TEST 134
8.4 BIOPSY 135
- 8.4.1 FINE NEEDLE ASPIRATION 136
- 8.4.2 NEEDLE CORE BIOPSY 136
8.5 BIOMARKER TEST 136
- 8.5.1 AQUAPORIN 1 (AQP1) 138
- 8.5.2 PERILIPIN (PLIN2) 138
- 8.5.3 N-METHYLTRANSFERASE (NMNT) 138
- 8.5.4 L-PLASTIN (LCP-1) 138
- 8.5.5 NM23A 138
8.6 GENETIC TEST 138
8.7 OTHERS 139

9 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141

9.1 OVERVIEW 142
9.2 STAGE I 145
9.3 STAGE II 145
9.4 STAGE III 146
9.5 STAGE IV 147

10 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148

10.1 OVERVIEW 149
10.2 RENAL CELL CARCINOMA 153
- 10.2.1 IMAGING 154
- 10.2.2 BLOOD TEST 154
- 10.2.3 BIOPSY 154
- 10.2.4 BIOMARKER TEST 154
- 10.2.5 GENETIC TEST 154
- 10.2.6 OTHERS 154
10.3 CLEAR CELL RENAL CELL CARCINOMA 154
- 10.3.1 IMAGING 156
- 10.3.2 BLOOD TEST 156
- 10.3.3 BIOPSY 156
- 10.3.4 BIOMARKER TEST 156
- 10.3.5 GENETIC TEST 156
- 10.3.6 OTHERS 156
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
- 10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
  - 10.4.1.1 IMAGING 158
  - 10.4.1.2 BLOOD TEST 158
  - 10.4.1.3 BIOPSY 158
  - 10.4.1.4 BIOMARKER TEST 158
  - 10.4.1.5 GENETIC TEST 158
  - 10.4.1.6 OTHERS 158
- 10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
  - 10.4.2.1 IMAGING 159
  - 10.4.2.2 BLOOD TEST 159
  - 10.4.2.3 BIOPSY 159
  - 10.4.2.4 BIOMARKER TEST 159
  - 10.4.2.5 GENETIC TEST 159
  - 10.4.2.6 OTHERS 159

11 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160

11.1 OVERVIEW 161
11.2 INSTRUMENT BASED PRODUCTS 165
- 11.2.1 IMAGING 166
- 11.2.2 BIOPSY 166
11.3 PLATFORM BASED PRODUCTS 166
- 11.3.1 NEXT GENERATION SEQUENCING 168
- 11.3.2 MICROARRAYS 168
- 11.3.3 PCR 169
- 11.3.4 OTHERS 169
11.4 KITS AND REAGENTS 169
- 11.4.1 RENAL CANCER PANELS 171
- 11.4.2 RENAL CANCER ANTIBODIES 171
11.5 OTHER CONSUMABLES 171

12 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172

12.1 OVERVIEW 173
12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
12.3 NEXT GENERATION SEQUENCING 176
12.4 FLUORIMMUNOASSAY 177
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
12.6 IMMUNOHISTOCHEMICAL 179
12.7 OTHERS 179

13 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181

13.1 OVERVIEW 182
13.2 SCREENING 185
- 13.2.1 INSTRUMENT BASED PRODUCTS 186
- 13.2.2 PLATFORM BASED PRODUCTS 186
- 13.2.3 KITS AND REAGENTS 186
- 13.2.4 OTHER CONSUMABLES 186
13.3 DIAGNOSTIC AND PREDICTIVE 186
- 13.3.1 INSTRUMENT BASED PRODUCTS 187
- 13.3.2 PLATFORM BASED PRODUCTS 187
- 13.3.3 KITS AND REAGENTS 187
- 13.3.4 OTHER CONSUMABLES 187
13.4 PROGNOSTIC 188
- 13.4.1 INSTRUMENT BASED PRODUCTS 189
- 13.4.2 PLATFORM BASED PRODUCTS 189
- 13.4.3 KITS AND REAGENTS 189
- 13.4.4 OTHER CONSUMABLES 189
13.5 RESEARCH 189
- 13.5.1 INSTRUMENT BASED PRODUCTS 190
- 13.5.2 PLATFORM BASED PRODUCTS 190
- 13.5.3 KITS AND REAGENTS 190
- 13.5.4 OTHER CONSUMABLES 191

14 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192

14.1 OVERVIEW 193
14.2 HOSPITALS 196
14.3 DIAGNOSTIC CENTERS 196
14.4 CANCER RESEARCH CENTERS 197
14.5 ACADEMIC INSTITUTES 198
14.6 AMBULATORY SURGICAL CENTERS 198
14.7 OTHERS 199

15 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200

15.1 OVERVIEW 201
15.2 DIRECT TENDER 204
15.3 RETAIL SALES 204
15.4 OTHERS 205

16 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206

16.1 EUROPE 207
- 16.1.1 GERMANY 223
- 16.1.2 FRANCE 232
- 16.1.3 UNITED KINGDOM 241
- 16.1.4 ITALY 250
- 16.1.5 SPAIN 259
- 16.1.6 RUSSIA 268
- 16.1.7 NETHERLANDS 277
- 16.1.8 POLAND 286
- 16.1.9 SWITZERLAND 295
- 16.1.10 BELGIUM 304
- 16.1.11 SWEDEN 313
- 16.1.12 NORWAY 322
- 16.1.13 DENMARK 331
- 16.1.14 FINLAND 340
- 16.1.15 TURKEY 349
- 16.1.16 REST OF EUROPE 358

17 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 359

17.1 COMPANY SHARE ANALYSIS: EUROPE 359

18 SWOT ANALYSIS 360

19 COMPANY PROFILE 361

19.1 CANON MEDICAL SYSTEMS CORPORATION 361
- 19.1.1 COMPANY SNAPSHOT 361
- 19.1.2 REVENUE ANALYSIS 361
- 19.1.3 COMPANY PROFILE 362
- 19.1.4 PRODUCT PORTFOLIO 362
- 19.1.5 RECENT DEVELOPMENT 362
19.2 KONINKLIJKE PHILIPS N.V. 363
- 19.2.1 COMPANY SNAPSHOT 363
- 19.2.2 REVENUE ANALYSIS 363
- 19.2.3 COMPANY PROFILE 364
- 19.2.4 PRODUCT PORTFOLIO 364
- 19.2.5 RECENT DEVELOPMENTS 365
19.3 GENERAL ELECTRIC COMPANY 366
- 19.3.1 COMPANY SNAPSHOT 366
- 19.3.2 REVENUE ANALYSIS 366
- 19.3.3 COMPANY PROFILE 367
- 19.3.4 PRODUCT PORTFOLIO 367
- 19.3.5 RECENT DEVELOPMENTS 368
19.4 SIEMENS HEALTHCARE GMBH 369
- 19.4.1 COMPANY SNAPSHOT 369
- 19.4.2 REVENUE ANALYSIS 369
- 19.4.3 COMPANY PROFILE 370
- 19.4.4 PRODUCT PORTFOLIO 370
- 19.4.5 RECENT DEVELOPMENT 371
19.5 GRAIL 372
- 19.5.1 COMPANY SNAPSHOT 372
- 19.5.2 PRODUCT PORTFOLIO 372
- 19.5.3 RECENT DEVELOPMENTS 372
19.6 AMBRY GENETICS 374
- 19.6.1 COMPANY SNAPSHOT 374
- 19.6.2 PRODUCT PORTFOLIO 374
- 19.6.3 RECENT DEVELOPMENT 374
19.7 BIOVENDOR R&D 375
- 19.7.1 COMPANY SNAPSHOT 375
- 19.7.2 PRODUCT PORTFOLIO 375
- 19.7.3 RECENT DEVELOPMENT 375
19.8 BLUEPRINT GENETICS OY. 376
- 19.8.1 COMPANY SNAPSHOT 376
- 19.8.2 PRODUCT PORTFOLIO 376
- 19.8.3 RECENT DEVELOPMENT 376
19.9 CD GENOMICS 377
- 19.9.1 COMPANY SNAPSHOT 377
- 19.9.2 PRODUCT PORTFOLIO 377
- 19.9.3 RECENT DEVELOPMENT 377
19.10 CENTOGENE N.V. 378
- 19.10.1 COMPANY SNAPSHOT 378
- 19.10.2 REVENUE ANALYSIS 378
- 19.10.3 PRODUCT PORTFOLIO 379
- 19.10.4 RECENT DEVELOPMENT 379

19.11 CREATIVE DIAGNOSTICS 380
- 19.11.1 COMPANY SNAPSHOT 380
- 19.11.2 PRODUCT PORTFOLIO 380
- 19.11.3 RECENT DEVELOPMENT 380
19.12 FUJIFILM CORPORATION 381
- 19.12.1 COMPANY SNAPSHOT 381
- 19.12.2 REVENUE ANALYSIS 381
- 19.12.3 PRODUCT PORTFOLIO 382
- 19.12.4 RECENT DEVELOPMENTS 382
19.13 GENEDX, LLC 383
- 19.13.1 COMPANY SNAPSHOT 383
- 19.13.2 REVENUE ANALYSIS 383
- 19.13.3 PRODUCT PORTFOLIO 384
- 19.13.4 RECENT DEVELOPMENT 384
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY 385
- 19.14.1 COMPANY SNAPSHOT 385
- 19.14.2 PRODUCT PORTFOLIO 385
- 19.14.3 RECENT DEVELOPMENT 385
19.15 ILLUMINA, INC. 386
- 19.15.1 COMPANY SNAPSHOT 386
- 19.15.2 REVENUE ANALYSIS 386
- 19.15.3 PRODUCT PORTFOLIO 387
- 19.15.4 RECENT DEVELOPMENT 387
19.16 INVITAE CORPORATION 388
- 19.16.1 COMPANY SNAPSHOT 388
- 19.16.2 REVENUE ANALYSIS 388
- 19.16.3 PRODUCT PORTFOLIO 389
- 19.16.4 RECENT DEVELOPMENT 389
19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 390
- 19.17.1 COMPANY SNAPSHOT 390
- 19.17.2 REVENUE ANALYSIS 390
- 19.17.3 PRODUCT PORTFOLIO 391
- 19.17.4 RECENT DEVELOPMENTS 391
19.18 MYRIAD GENETICS, INC. 392
- 19.18.1 COMPANY SNAPSHOT 392
- 19.18.2 REVENUE ANALYSIS 392
- 19.18.3 PRODUCT PORTFOLIO 393
- 19.18.4 RECENT DEVELOPMENT 393
19.19 THERMO FISHER SCIENTIFIC INC. 394
- 19.19.1 COMPANY SNAPSHOT 394
- 19.19.2 REVENUE ANALYSIS 394
- 19.19.3 PRODUCT PORTFOLIO 395
- 19.19.4 RECENT DEVELOPMENT 395
19.20 QIAGEN 396
- 19.20.1 COMPANY SNAPSHOT 396
- 19.20.2 REVENUE ANALYSIS 396
- 19.20.3 PRODUCT PORTFOLIO 397
- 19.20.4 RECENT DEVELOPMENT 397

20 QUESTIONNAIRE 398

21 RELATED REPORTS 402

LIST OF TABLES

TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS 76
TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER 78
TABLE 3 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 89
TABLE 4 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 5 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 91
TABLE 6 EUROPE BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 7 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 8 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 93
TABLE 9 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 94
TABLE 10 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
TABLE 11 EUROPE GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 12 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 13 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 101
TABLE 14 EUROPE STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 15 EUROPE STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 16 EUROPE STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 17 EUROPE STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 18 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 109
TABLE 19 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 20 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 21 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 22 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
TABLE 23 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 24 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 114
TABLE 25 EUROPE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 26 EUROPE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
TABLE 27 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 121
TABLE 28 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 29 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 123
TABLE 30 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 123
TABLE 31 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 123
TABLE 32 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 33 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 125
TABLE 34 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 125
TABLE 35 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 125
TABLE 36 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
TABLE 37 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 127
TABLE 38 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 127
TABLE 39 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 127
TABLE 40 EUROPE OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
TABLE 41 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 132
TABLE 42 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
TABLE 43 EUROPE NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
TABLE 44 EUROPE FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
TABLE 45 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
TABLE 46 EUROPE IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
TABLE 47 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
TABLE 48 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 141
TABLE 49 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
TABLE 50 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 142
TABLE 51 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 144
TABLE 52 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 144
TABLE 53 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
TABLE 54 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 145
TABLE 55 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
TABLE 56 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 147
TABLE 57 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 152
TABLE 58 EUROPE HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
TABLE 59 EUROPE DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
TABLE 60 EUROPE CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
TABLE 61 EUROPE ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 155
TABLE 62 EUROPE AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 156
TABLE 63 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 156
TABLE 64 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 160
TABLE 65 EUROPE DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 161
TABLE 66 EUROPE RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 162
TABLE 67 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 162
TABLE 68 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 170
TABLE 69 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 70 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 71 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 72 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 73 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 172
TABLE 74 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 172
TABLE 75 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 172
TABLE 76 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
TABLE 77 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 173
TABLE 78 EUROPE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 173
TABLE 79 EUROPE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 174
TABLE 80 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
TABLE 81 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
TABLE 82 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 174
TABLE 83 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 175
TABLE 84 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
TABLE 85 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 175
TABLE 86 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 175
TABLE 87 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 176
TABLE 88 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 176
TABLE 89 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 176
TABLE 90 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 176
TABLE 91 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 177
TABLE 92 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 177
TABLE 93 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 177
TABLE 94 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 178
TABLE 95 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 178
TABLE 96 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 178
TABLE 97 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 179
TABLE 98 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 180
TABLE 99 GERMANY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 180
TABLE 100 GERMANY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 180
TABLE 101 GERMANY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 181
TABLE 102 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 181
TABLE 103 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 181
TABLE 104 GERMANY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
TABLE 105 GERMANY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 182
TABLE 106 GERMANY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 182
TABLE 107 GERMANY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 183
TABLE 108 GERMANY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 183
TABLE 109 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 183
TABLE 110 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 184
TABLE 111 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 184
TABLE 112 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 184
TABLE 113 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 184
TABLE 114 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 185
TABLE 115 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 185
TABLE 116 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 185
TABLE 117 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 185
TABLE 118 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 185
TABLE 119 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 186
TABLE 120 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 186
TABLE 121 GERMANY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 186
TABLE 122 GERMANY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 187
TABLE 123 GERMANY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 187
TABLE 124 GERMANY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 187
TABLE 125 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 188
TABLE 126 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 188
TABLE 127 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 189
TABLE 128 FRANCE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 189
TABLE 129 FRANCE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 189
TABLE 130 FRANCE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 190
TABLE 131 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 190
TABLE 132 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 190
TABLE 133 FRANCE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 191
TABLE 134 FRANCE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 191
TABLE 135 FRANCE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 191
TABLE 136 FRANCE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 192
TABLE 137 FRANCE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 192
TABLE 138 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 192
TABLE 139 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 193
TABLE 140 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 193
TABLE 141 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 193
TABLE 142 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 193
TABLE 143 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 194
TABLE 144 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 194
TABLE 145 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 194
TABLE 146 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 194
TABLE 147 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 194
TABLE 148 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 195
TABLE 149 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 195
TABLE 150 FRANCE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 195
TABLE 151 FRANCE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 196
TABLE 152 FRANCE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 196
TABLE 153 FRANCE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 196
TABLE 154 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 197
TABLE 155 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 197
TABLE 156 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 198
TABLE 157 UNITED KINGDOM IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 198
TABLE 158 UNITED KINGDOM BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 198
TABLE 159 UNITED KINGDOM BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 199
TABLE 160 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 199
TABLE 161 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 199
TABLE 162 UNITED KINGDOM RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
TABLE 163 UNITED KINGDOM CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 200
TABLE 164 UNITED KINGDOM NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 200
TABLE 165 UNITED KINGDOM PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 201
TABLE 166 UNITED KINGDOM CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 201
TABLE 167 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 201
TABLE 168 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 202
TABLE 169 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 202
TABLE 170 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 202
TABLE 171 UNITED KINGDOM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 202

LIST OF FIGURES

FIGURE 1 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 47
FIGURE 2 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 50
FIGURE 3 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 51
FIGURE 4 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 52
FIGURE 5 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 52
FIGURE 6 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 53
FIGURE 7 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 55
FIGURE 8 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 57
FIGURE 9 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 58
FIGURE 10 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 62
FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 63
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030 63
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE KIDNEY CANCER DIAGNOSTICS MARKET 74
FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020) 76
FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020) 76
FIGURE 16 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 86
FIGURE 17 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 87
FIGURE 18 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 87
FIGURE 19 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 88
FIGURE 20 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022 98
FIGURE 21 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION) 99
FIGURE 22 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030) 99
FIGURE 23 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE 100
FIGURE 24 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022 106
FIGURE 25 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION) 107
FIGURE 26 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030) 107
FIGURE 27 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE 108
FIGURE 28 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022 118
FIGURE 29 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION) 119
FIGURE 30 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030) 119
FIGURE 31 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE 120
FIGURE 32 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022 129
FIGURE 33 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION) 130
FIGURE 34 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030) 130
FIGURE 35 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE 131
FIGURE 36 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022 138
FIGURE 37 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION) 139
FIGURE 38 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030) 139
FIGURE 39 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE 140
FIGURE 40 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022 149
FIGURE 41 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 150
FIGURE 42 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 150
FIGURE 43 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 151
FIGURE 44 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 157
FIGURE 45 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 158
FIGURE 46 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 158
FIGURE 47 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 159
FIGURE 48 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 164
FIGURE 49 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 166
FIGURE 50 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 166
FIGURE 51 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 167
FIGURE 52 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 168
FIGURE 53 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 315